ArticleGut pathogens2025
Patients with inflammatory bowel disease exhibit increased susceptibility to HCoV-NL63.
Article in Gut pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunocompromised inflammatory bowel disease (IBD) patients may develop life-threatening pneumonia and bronchiolitis upon HCoV-NL63 infection. However, little is known whether these patients will be more susceptible to HCoV-NL63 infection. We compared the expression of ACE2 in different tissues and cell lines. Besides, the susceptibility of colonic cells to HCoV-NL63 was assessed. We then examined the expression of ACE2 in the colonic mucosa from IBD patients and animal models, and in the inflammatory colonic cells. The susceptibility of inflammatory colonic cells to HCoV-NL63 was detected using a pseudovirus-based system. Pseudovirus based neutralization assay was used to quantify the neutralizing antibodies to HCoV-NL63 in patients with IBD and healthy controls. ACE2 was abundantly expressed in the colonic tissue and cells. And colonic cells were susceptible to pseudotyped HCoV-NL63. The expression of ACE2 was increased in the colonic mucosa from IBD patients and animal models, and in inflammatory colonic cells. Inflammatory colonic cells were more susceptible to pseudotyped HCoV-NL63. Besides, reduced protective neutralizing antibody titers were seen in patients with IBD, especially for male or older IBD patients. These results suggest IBD patients may be particularly susceptible to infection with HCoV-NL63 and thus extra precautions should be taken to prevent them from infection. Further mechanistic studies are needed to support our findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.